Abstract: A primer pair that includes a forward primer and a reverse primer is used to amplify a nucleic acid from a pathogen associated with a skin, hair and nail infection that includes SEQ ID NO: 22. A nucleic acid capable of hybridizing specifically to a nucleic acid sequence from a pathogen associated with a skin, hair and nail infection that includes SEQ ID NO: 22 is provided. A carrier that includes the nucleic acid is provided. A method can be used to detect in a sample a nucleic acid sequence including SEQ ID NO: 22 from a pathogen associated with a skin, hair, and nail infection. The primer pair, the nucleic acid, or the carrier may be useful for the diagnosis of a disease. A kit including the primer pair, the nucleic acid, and/or the carrier may be useful for the diagnosis of a disease.

Abstract: A primer pair that includes a forward primer and a reverse primer is used to amplify a nucleic acid from a pathogen associated with a skin, hair and nail infection that includes SEQ ID NO: 22. A nucleic acid capable of hybridizing specifically to a nucleic acid sequence from a pathogen associated with a skin, hair and nail infection that includes SEQ ID NO: 22 is provided. A carrier that includes the nucleic acid is provided. A method can be used to detect in a sample a nucleic acid sequence including SEQ ID NO: 22 from a pathogen associated with a skin, hair and nail infection. The primer pair, the nucleic acid, or the carrier may be useful for the diagnosis of a disease. A kit including the primer pair, the nucleic acid, and/or the carrier may be useful for the diagnosis of a disease.

Abstract: The present invention relates to a primer pair comprising a forward primer and a reverse primer for amplifying a nucleic acid from a pathogen associated with a skin, hair and nail infection comprising SEQ ID NO:22, a nucleic acid capable of hybridizing specifically to a nucleic acid sequence from a pathogen associated with a skin, hair and nail infection comprising SEQ ID NO:22, a carrier comprising the nucleic acid, a method comprising the step detecting in a sample a nucleic acid sequence comprising SEQ ID NO:22 from a pathogen associated with a skin, hair and nail infection, a use of the primer pair, the nucleic acid or the carrier for the diagnosis of a disease and a kit comprising the primer pair, the nucleic acid and/or the carrier for the diagnosis of a disease.

Abstract: The present invention relates to a primer pair comprising a forward primer and a reverse primer for amplifying a nucleic acid from a pathogen associated with a skin, hair and nail infection comprising SEQ ID NO:22, a nucleic acid capable of hybridizing specifically to a nucleic acid sequence from a pathogen associated with a skin, hair and nail infection comprising SEQ ID NO:22, a carrier comprising the nucleic acid, a method comprising the step detecting in a sample a nucleic acid sequence comprising SEQ ID NO:22 from a pathogen associated with a skin, hair and nail infection, a use of the primer pair, the nucleic acid or the carrier for the diagnosis of a disease and a kit comprising the primer pair, the nucleic acid and/or the carrier for the diagnosis of a disease.

Abstract: A method for identifying the agonistic activity of a target compound on a potassium channel by a) providing a population of cells expressing a potassium channel and, optionally providing, a protein-based fluorescent-optical voltage sensor, b) if necessary, incubating the cells with a voltage-sensitive fluorescent dye, c) adding the target compound to the reaction batch of a) or b), d) determining a value F1 of the fluorescence intensity of the cells, e) adding potassium ions in a physiologically acceptable concentration f) determining a value F2 of the fluorescence intensity of the cells, and g) comparing the fluorescence intensity F2 with the fluorescence intensity F1 and determining the agonistic activity of the target compound on a potassium channel therefrom. A potassium channel agonist isolated and purified by this method, pharmaceutical formulations containing the same, and their use for the treatment of a disease in which potassium channels are involved.